非小细胞肺癌新辅助免疫治疗进展  

Progress of Neoadjuvant Immunotherapy for Non-small Cell Lung Cancer

作　　者：郭超[1] 张家齐[1] 李单青 Chao GUO;Jiaqi ZHANG;Shanqing LI(Department of Thoracic Surgery,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100730,China)

机构地区：[1]中国医学科学院,北京协和医学院,北京协和医院胸外科,北京100730

出　　处：《中国肺癌杂志》2022年第7期524-533,共10页Chinese Journal of Lung Cancer

摘　　要：非小细胞肺癌新辅助免疫治疗发展迅速,包括新辅助单药/双药免疫治疗、新辅助化疗/放疗联合免疫治疗等;部分临床试验结果显示,在经过选择的非小细胞肺癌患者中,新辅助免疫治疗具有可观的病理缓解率并产生可观察到的临床获益,而且毒副作用可耐受。Nivolumab联合化疗已于近期被美国食品药物监督管理局(Food and Drug Administration,FDA)批准用于非小细胞肺癌新辅助治疗。非小细胞肺癌新辅助免疫治疗的长期疗效、副作用以及手术相关问题需要进一步关注。Neoadjuvant immunotherapy,including neoadjuvant single-or dual-drug immunotherapy or combined immunotherapy with chemotherapy or radiotherapy,has witnessed a rapid development in non-small cell lung cancer.Clinical trials exhibited the encouraging pathological responses and certain clinical benefits in selected patients,with tolerable toxicity.Nivolumab with chemotherapy has been approved by Food and Drug Administration(FDA)as the first immunotherapy-based treatment for non-small cell lung cancer in the neoadjuvant treatment setting.There is the need for further evaluation of longterm efficacy,side effects or surgical issues for neoadjuvant immunotherapy in non-small cell lung cancer.

关 键 词：肺肿瘤 新辅助治疗 免疫治疗 

分 类 号：R734.2[医药卫生—肿瘤]